首页 | 本学科首页   官方微博 | 高级检索  
文章检索
  按 检索   检索词:      
出版年份:   被引次数:   他引次数: 提示:输入*表示无穷大
  收费全文   1357844篇
  免费   106135篇
  国内免费   2157篇
耳鼻咽喉   19178篇
儿科学   46788篇
妇产科学   36787篇
基础医学   194666篇
口腔科学   36038篇
临床医学   118460篇
内科学   273359篇
皮肤病学   29309篇
神经病学   108648篇
特种医学   54658篇
外国民族医学   665篇
外科学   206435篇
综合类   27417篇
现状与发展   2篇
一般理论   447篇
预防医学   105544篇
眼科学   29212篇
药学   99831篇
  2篇
中国医学   2535篇
肿瘤学   76155篇
  2019年   10614篇
  2018年   15044篇
  2017年   11539篇
  2016年   12651篇
  2015年   14353篇
  2014年   19908篇
  2013年   29760篇
  2012年   41526篇
  2011年   43668篇
  2010年   25773篇
  2009年   24829篇
  2008年   41483篇
  2007年   44227篇
  2006年   44298篇
  2005年   42994篇
  2004年   41439篇
  2003年   39941篇
  2002年   38910篇
  2001年   66577篇
  2000年   68895篇
  1999年   58365篇
  1998年   15358篇
  1997年   13816篇
  1996年   14254篇
  1995年   14149篇
  1994年   13427篇
  1993年   12364篇
  1992年   46152篇
  1991年   44914篇
  1990年   43599篇
  1989年   41402篇
  1988年   38093篇
  1987年   37312篇
  1986年   34631篇
  1985年   33286篇
  1984年   24855篇
  1983年   20858篇
  1982年   12047篇
  1981年   10955篇
  1979年   21902篇
  1978年   15139篇
  1977年   12792篇
  1976年   11912篇
  1975年   12855篇
  1974年   14945篇
  1973年   14410篇
  1972年   13210篇
  1971年   11979篇
  1970年   11256篇
  1969年   10210篇
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Neuroscience and Behavioral Physiology - We present here results from analysis of the formation of brain bioelectrical activity in children and adolescents living in the northern region of Russia...  相似文献   
2.
The Extracellular Vesicle Flow Cytometry Working Group ( http://www.evflowcytometry.org ) is formed by members of the International Society for Extracellular Vesicles (ISEV), the International Society for Advancement of Cytometry (ISAC), and the International Society on Thrombosis and Haemostasis (ISTH). This working group of flow cytometry experts develops guidelines for best practices regarding flow cytometry detection of extracellular vesicles. To improve rigor and standardization, this working group published a framework outlining the minimal information to report about a flow cytometry experiment on extracellular vesicles (MIFlowCyt-EV) in the Journal of Extracellular Vesicles, the ISEV journal, in 2020. In parallel, an article explaining MIFlowCyt-EV was published in Cytometry Part A, one of the ISAC journals, and now will be introduced to the ISTH as an SSC Communication in the Journal of Thrombosis and Haemostasis. The goal of this SSC Communication is to explain why flow cytometry is becoming the instrument of choice to characterize single extracellular vesicles, the obstacles that have been identified and (mostly) overcome by developing procedures to calibrate flow cytometers, and the relevance of reporting minimal information to improve reliability and reproducibility of experiments in which flow cytometers are used for characterization of extracellular vesicles.  相似文献   
3.
4.
5.
6.
7.
8.
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible.  相似文献   
9.
Medicine, Health Care and Philosophy - In this paper, I will provide a phenomenological analysis of somatic obsessions at times present in obsessive–compulsive disorder. I will compare two...  相似文献   
10.
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号